Commodore Capital’s Protagonist Therapeutics PTGX Stock Holding History

Commodore Capital’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-450,000	Closed	-$39.3M	–	40
2025 Q4	$39.3M	Sell	450,000 -575,000	-56%	-$47.1M	2.62%	17
2025 Q3	$68.1M	Sell	1,025,000 -50,000	-5%	-$2.84M	3.32%	13
2025 Q2	$59.4M	Buy	+1,075,000	New	+$51.6M	4.19%	9
2022 Q2	–	Sell	-331,886	Closed	-$7.86M	–	29
2022 Q1	$7.86M	Sell	331,886 -473,687	-59%	-$13.3M	1.76%	19
2021 Q4	$27.6M	Buy	805,573 +307,494	+62%	+$9.72M	6.38%	6
2021 Q3	$8.83M	Buy	498,079 +287,479	+137%	+$12.3M	2.33%	18
2021 Q2	$9.45M	Sell	210,600 -139,000	-40%	-$4.59M	3.29%	14
2021 Q1	$9.05M	Buy	349,600 +2,100	+0.6%	+$53.1K	3.61%	9
2020 Q4	$7.01M	Buy	+347,500	New	+$7.48M	3.81%	13

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Commodore Capital's PTGX Position: Q1 2026 in Review

Commodore Capital sold out of Protagonist Therapeutics (PTGX) in Q1 2026, closing a stake of 450,000 shares — an estimated $39.3M sold.

Commodore Capital first reported a position in PTGX in Q4 2020 and held it in 9 quarters. The position peaked at $68.1M in Q3 2025. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

Commodore Capital reported no remaining Protagonist Therapeutics position as of Q1 2026 after selling out during the quarter.
Commodore Capital sold 450,000 Protagonist Therapeutics shares in Q1 2026, an estimated $39.3M.
Commodore Capital first reported a position in Protagonist Therapeutics in Q4 2020 and held it in 9 quarters.
Commodore Capital's Protagonist Therapeutics position peaked at $68.1M in Q3 2025.
317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Commodore Capital's 13F filing for Q1 2026, filed 15 May 2026.